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Context: Cardiovascular disease (CVD) costs the economy €210 billion per year in Europe. 
There is an association between low-density lipoprotein cholesterol (LDL-C) and CVD risk.
Objective: To evaluate the cost and effectiveness of LopiGLIK® (LOPI) in lowering LDL-C 
and CVD risk.
Design: Single blind multicenter randomized controlled trial; patients were divided into two 
groups, subjected to centralized randomization.
Setting: Four Italian regions.
Participants: Thirty-one physicians enrolled 573 adult patients with mild hypercholesterolemia 
between January 2016 and January 2018.
Intervention: Patients were treated for 16 weeks either with LOPI (intervention) or Armolipid 
Plus® (AP; control).
Outcome measures: Primary outcome: percentage of patients who achieved LDL-C <130 
mg/dL. Secondary outcomes: reduction of HbA1c, survival analysis and HR linked to 38.67 
mg/dL reduction of LDL-C and 1% reduction of HbA1c. Costs were assessed per unit and cure.
Results: Three hundred and seventy patients treated with LOPI and 203 treated with AP were 
randomized and completed the study. At baseline 8.9% (n=18) patients treated with AP and 
9.5% (n=35) treated with LOPI had LDL-C levels <130  mg/dL (P=0.815). At the 16-week 
follow-up, 41.4% (n=84) of patients treated with AP and 67.6% (n=250) with LOPI achieved 
LDL-C levels <130  mg/dL (P<0.001). LOPI patients were three times more likely to achieve 
LDL-C levels <130  mg/dL; adjusted OR 2.97 (95% CI; 2.08–4.24; P<0.001), number needed 
to treat was four (95% CI; 5.60–2.90; P<0.001). Survival analysis demonstrated the superiority 
of LOPI vs AP relative to 38.67  mg/dL LDL-C reduction (P<0.002); HR was 0.761 (95% CI; 
0.62–0.94; P<0.001). Both products reduced the HbA1c without a significant difference between 
them (P=0.156). Survival analysis and HR (0.91; 95% CI; 0.70–1.18) estimated for 1% HbA1c 
reduction, showed differences between LOPI and AP, which were not significant (P=0.411; 
P=0.464). The cost of LOPI was €2.11 (unit), €211 (cure), and AP €3.77 and €377, respectively.
Conclusion: LOPI appeared more effective and less expensive than AP in lowering LDL-C 
and CVD risk.
Trial registration: NCT02898805, September 8, 2016.
Keywords: hypercholesterolemia, nutraceuticals, effectiveness, cardiovascular risk reduction
Introduction
The WHO confirmed that cardiovascular disease (CVD) is the number one cause 
of death globally; 17.7 million people died in 2015, representing 31% of all global 
deaths.1 Statistics published in 2017 suggest that CVD is the major cause of mortality 
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in Europe as a whole being responsible for over 3.9 million 
deaths a year, equivalent to 45% of all deaths.2 CVD is thus 
a major cause of economic and human cost for Europe.3 The 
latest estimates depict overall costs of CVD in Europe as 
€210 billion a year, where 53% (€111 billion) is due to direct 
health care costs, 26% (€54 billion) to productivity losses, 
and 21% (45€ billion) to the informal care of people with 
CVD. Ischemic heart disease  (IHD) was estimated to cost 
the economy €59 billion yearly and stroke €45 billion per 
year. The Centre for Economic and Business Research report 
in 2014 provided useful information regarding the economic 
costs of CVD from 2014 to 2020 in six European economies 
(including Italy), predicting that health care costs from CVD 
will increase further across all economies until the end of 
the decade.3 Reviewing the evidence base for modifiable risk 
factors, the INTERHART study, conducted in 52 countries, 
found abnormal lipid levels to be the highest attributable risk 
(49%) of a myocardial infarction.4 The Framingham Heart 
Study demonstrated that men and women were 1.5 times more 
likely to develop clinically significant coronary heart disease 
(CHD) if their low-density lipoprotein cholesterol (LDL-C) 
was >160 mg/dL compared to a reference population with 
LDL-C <130 mg/dL.5 The epidemiologic investigations have 
validated LDL-C as an independent predictor of CVD risk.6 
In the Atherosclerosis Risk in Communities (ARIC) study, 
the risk of a CHD event was elevated by ~40% for every 39 
mg/dL incremental increase in LDL-C.7
The Cholesterol Treatment Trialists’ (CTT) collaboration 
has demonstrated that lowering LDL-C reduces the risk of 
major vascular events (heart attacks, stroke or coronary revas-
cularization procedures) by approximately one fifth (20%) 
for each 38.67 mg/dL (38.67 mg/dL =1 mmol/L) reduction 
of LDL-C achieved.8
During the past decades many studies have been published 
on cholesterol-lowering medications, and more recently the 
current international guidelines for the management of dyslip-
idemia suggest that nutraceuticals (NUTs) can be used either 
as alternatives or in addition to lipid-lowering medications.9
The Italian Society of Diabetology and the Italian Society 
for the Study of Arteriosclerosis (SISA) suggested that the 
cholesterol-lowering effect of some NUTs is not only con-
sistent, but it is also supported by a good level of scientific 
evidence.10 In fact, a recent systematic review and meta-
analysis of randomized controlled trials, including 14 trials 
(1,670 subjects in the NUTs arm and 1,489 subjects in the 
control arm), showed that the a combination of NUTs, similar 
to the ones used in this study, was associated with signifi-
cant reductions of plasma total cholesterol (26.15 mg/dL), 
LDL-C (23.85 mg/dL), triglycerides (13.83 mg/dL), and 
glucose levels (2.59 mg/dL), and a modest but significant 
increase of plasma high-density lipoprotein cholesterol levels 
(2.53 mg/dL).11
NUT are forms of compounds with biological activity 
commonly used to improve health in dosages exceeding 
those usually obtainable from food.12 In light of published 
evidence, it is advisable to suggest strategies and action 
plans using NUTs that could help to reduce the hazard/risk 
of CVD events and their associated costs to the health care 
system and society as well.
aim
This study aimed to evaluate the comparative effectiveness 
and cost of a novel NUT product LopiGLIK® (LOPI) which 
contains berberine (531 mg), red yeast rice powder (220 mg; 
3.3 mg monacolin K), Morus alba (200 mg), vs Armolipid 
Plus® (AP) (available since 2006) which contains policosanol 
(10 mg), red yeast rice (200 mg; 3 mg monacolin K), berber-
ine (500 mg), astaxanthin (0.5 mg), folic acid (200 mcg), and 
coenzyme Q10 (2 mg). AP has a documented lipid-lowering 
effect in lowering LDL-C and CVD risk.13–15
The key research questions were: is LOPI more effective 
than AP in: 
•	 Reducing	the	LDL-C	levels	to	<130	mg/dL?
•	 Reducing	the	HR	of	CVD	linked	to	38.67	mg/dL	reduc-
tion	of	LDL-C	levels?
•	 Reducing	the	HbA1C	levels	by	1%?
•	 Reducing	 the	HR	of	CVD	 linked	 to	 1%	 reduction	of	
HbA1c	levels?
It was also relevant to assess the cost of NUTs for the 
duration of the treatment.
Methods
Study design
This was an experimental study, conducted using a mul-
ticenter, randomized, controlled, single blind trial design 
assessing the effectiveness and cost of LOPI vs AP (Figure 1).
Study timeline
The study was conducted between January 2016 and Janu-
ary 2018.
intervention
Both products aimed to lower LDL-C levels. The AP-treated 
patients represented the control group, with LOPI-treated 
patients being the intervention group.
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Outcome measures
primary outcome
•	 Percentage	 of	 patients	 who	 achieved	 LDL-C	 
<130 mg/dL.
LDL-C levels were assessed at baseline and after 16 weeks, 
using a threshold of LDL-C <130 mg/dL.5
Secondary outcome measures
•	 Survival	analysis	and	HR	linked	to	38.67	mg/dL	reduction	
of LDL-C levels;16
•	 HbA1c	levels	assessed	at	baseline	and	after	16	weeks;
•	 survival	 analysis	 and	HR	 linked	 to	 1%	 reduction	 of	
HbA1c levels;17,18
•	 the	 cost	 of	 treatment	 for	 each	product	was	 calculated	
according to the primary outcome.
Study participants
inclusion criteria
•	 Age:	18–75	years	of	age;
•	 sex:	all;
•	 healthy	volunteers;
•	 total	cholesterol	<300	mg/dL;
•	 total	cholesterol	>200	mg/dL;
•	 cardiovascular	risk	<20% (according to 2016 European 
Guidelines on cardiovascular disease prevention).19
Exclusion criteria
•	 Pregnancy;
•	 documented	intolerance	to	one	or	more	components	of	
LOPI/AP;
•	 previous	cardiovascular	events;
Figure 1 CONSORT flow diagram showing the flow of patients through the study.
Abbreviations: ap, armolipid plus®; lOpi, lopiGliK®.
Assessed for eligibility (n=674)
Excluded (n=101)
Randomized (n=573)
Entered the trial
(n=573)
Group B patients
(n=370)
Group B patients
prescribed diet and
placebo (n=370)
Baseline values were
assessed using blood
sample (end of week 2)
Group B patients
received LOPI, 1 tablet
daily for 16 weeks +
diet (n=370)
Group B patients
analyzed (n=370)
Group A patients
analyzed (n=203)
Group A patients
received AP, 1 tablet
daily for 16 weeks + diet
(n=203) 
Baseline values were
assessed using blood
sample (end of week 2)
Group A patients
prescribed diet and
placebo (n=203)
Group A patients
(n=203) 
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•	 familial	severe	dyslipidemia;
•	 familial	high	cardiovascular	risk;
•	 hepatic	or	muscular	disorders;
•	 subjects	receiving	any	lipid-lowering	drugs	or	NUT	with	
lipid-lowering effect.
Patients were recruited by cardiovascular specialists and/
or general practitioners; each physician was asked to recruit 
the first 25 consecutive adult outpatients, according to the 
protocol approved by the Ethics Committee of the Federico 
II University of Naples. The subjects were enrolled in a ratio 
of 50/50% male/female ±10% comparable for age, in order 
to obtain a proper comparison between groups with similar 
demographic characteristics.
Randomization, allocation, and blinding
Patients were divided into two groups (A =AP and B =LOPI) 
and subjected to centralized randomization at the Hyper-
tension Outpatient Clinic at the Federico II University of 
Naples (Italy). The patient was the unit of randomization and 
intervention. During the first 2 weeks, both groups followed 
a prescribed diet and assumed a placebo. At the end of the 
2-week period and at the end of the study, blood glucose, 
HbA1c, fasting insulin, transaminase levels, and creatine 
phosphokinase were assessed under fasting conditions. Dur-
ing the following 16 weeks, patients in group A took one AP 
tablet daily immediately after a meal, and patients in group 
B took one LOPI tablet daily immediately after a meal. 
Patients followed the prescribed diet up until the end of the 
study. AP and LOPI tablets were provided free of charge by 
AkademyPharma.
Data collection
Thirty-one physicians working in different settings (hospital, 
university, general practice) collected data from patients in 
four regions, Basilicata, Campania, Emilia Romagna, and 
Toscana.
interim analysis
An interim analysis was published elsewhere.20
Data analysis
The percentage of missing values was 4.6%, data were 
missing at random and a multiple imputation technique was 
applied for replacing missing data.21
Each variable was analyzed using the Kolmogorov–
Smirnov test to check for normality; data were not normally 
distributed. Differences between groups (AP and LOPI) 
were assessed using Mann–Whitney U test for continuous 
variables, and Wilcoxon sign rank test was used for within-
group comparison. Chi square test for independence was used 
for categorical variables. The procedures were performed 
according to McCrum-Gardner (2008).22
analysis of the primary outcome
The primary outcome, reduction of LDL-C levels, was 
analyzed using a semi-parametric technique called general 
estimating equations (GEE), as suggested by Velentgas et al.23 
Binary logistic analysis was used, dichotomizing the primary 
outcome into reduced (LDL-C level <130 mg/dL) and not-
reduced (LDL-C level ≥130 mg/dL). The GEE model was 
used without adjustment, and then adjusted using the LDL-C 
values obtained at baseline. The relative risk (RR), the relative 
risk reduction (RRR), the absolute risk reduction (ARR), and 
the number needed to treat (NNT) were calculated using a 
bespoke Excel model. The results of the model were com-
pared to the results obtained using two online calculators: 
1) Centre for Evidence-Based Medicine of Toronto which 
also provided significance levels (P-value) and 95% CIs,24 
2) BMJ EBM toolbox statistical calculator.25
analysis of the secondary outcomes
The survival analysis was conducted using the Kaplan–Meier 
curve, with the log-rank (Mantel–Cox) option, aiming to 
estimate the survival curve, using 38.67 mg/dL of LDL-C 
reduction and 1% reduction of HbA1c as events of interest 
(censored data). The HR (also called instantaneous risk) 
which in our specific case could be considered equivalent 
to the RR of each outcome, was calculated using the Cox 
proportional hazards regression analysis for LDL-C and for 
the HbA1c adopting the same threshold of 38.67 mg/dL and 
1% HbA1c respectively.
A therapy or medication is deemed to be cost effective 
when the outcome is worth the cost relative to competing 
alternatives. In our case, due to economic and time constraints, 
it was not possible to collect direct medical costs, non-direct 
medical costs, and all indirect costs, but we assumed that 
these costs were similar. The only available cost during the 
study was the cost of the two NUTs, which were sold at the 
same price: €21.90 for a box of 20 tablets. The number of 
tablets needed for each patient for the entire duration of the 
study (16 weeks) was 112; the cost per patient was €122.64.
Both products were available from community pharma-
cies as over-the-counter medications but were neither paid 
for nor reimbursed by the Italian National Health Service.
The primary outcome was used for the calculation of the 
cost per unit and per cure, and the cost was based only on 
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the price of the NUT. Bang and Zhao (2012) suggested that 
the cost per unit and per cure conveys an intuitive meaning 
and interpretation that even lay persons can understand, but 
they added that this approach could be less relevant to health 
economics and decision-makers.26
product safety
A previous study assessed the safety and tolerability profiles 
of the two products concluding that they were similar.12 In 
this trial, safety was assessed by a specific questionnaire and 
clinical examination at each visit and by laboratory tests at 
the end of the run-in period and at the end of the study.
All analyses were conducted using the intention-to-treat 
approach and P<0.05 was considered statistically significant. 
Data analysis was performed using SPSS IBM version 24 
and Excel for MS Office 2016.
Results
The number of patients randomized was 573; 370 received 
LOPI and 203 AP, resulting in a 2:1 randomization ratio 
(Figure 1). A post hoc power calculation was conducted 
using G*Power version 3.1.93 (Allgemeine Psychologie 
und Arbeitspsychologie, Dusseldorf, Germany); the power 
attained by the study was >99% with an effect size (Cohen’s 
d) of 0.53, using a difference between the mean (mean rank) 
of 13 and alpha 0.05 (single-tailed, directional).
Baseline characteristics
The number of female patients was 113 (55.7%) in the AP 
group and 207 (55.9%) in the LOPI group. Nineteen differ-
ent items were assessed at baseline and only one, the level 
of HbA1c, presented a statistically significant difference 
(Table 1).
primary outcome
percentage of patients who achieved lDl-C  
<130 mg/dl
The percentage of patients with LDL-C <130 mg/dL at base-
line was 8.9% (18/203) in the AP group and 9.5% (35/370) 
in the LOPI group (P=0.815). At the end of the study 41.4% 
(84/203) of patients treated with AP and 67.6% (250/370) 
with LOPI achieved an LDL-C <130 mg/dL; this difference 
was statistically significant (P<0.001). The GEE analysis 
showed that patients in the LOPI group were almost three 
times more likely to achieve the target LDL-C levels (<130 
mg/dL). The unadjusted OR for the LOPI group was 2.95 
(95% CI 2.07–4.20; P<0.001), the adjusted OR was 2.97 
(95% CI 2.08–4.24; P<0.001). The percentage increase in 
Table 1 Baseline characteristics
AP LOPI P-value
Number of participants N=203 (35.4%) N=370 (64.6%)
Female, N (%)a 113 (55.7%) 207 (55.9%) 0.948
Median IQR Median IQR
age (years) 55.9 46.4 – 64.8 56.0 48.6 – 62.6 0.589
Height (cm) 166.0 160.0 – 174.0 166.0 160.0 – 173.0 0.655
Weight (kg) 78.0 68.5 – 88.0 78.0 69.0 – 87.0 0.861
Waist circumference (cm) 98.0 90.0 – 106.0 98.0 90.0 – 107.0 0.988
Systolic blood pressure (mmHg) 130.0 124.0 – 140.0 130.0 120.0 – 140.0 0.417
Diastolic blood pressure (mmHg) 80.0 76.0 – 85.0 80.0 76.8 – 85.0 0.681
Fasting insulin/glucose (mg/dl) 72.0 66.0 – 78.0 72.0 66.0 – 78.0 0.815
Total cholesterol (mg/dl) 240.0 224.0 – 258.0 240.0 224.8 – 255.0 0.804
lDl-C (mg/dl) 156.0 145.0 – 175.0 158.0 142.8 – 175.3 0.941
HDl-C (mg/dl) 50.0 41.0 – 58.0 48.0 40.0 – 59.0 0.232
TG (mg/dl) 144.0 102.0 – 180.0 148.0 105.8 – 186.3 0.420
Glycemia (mg/dl) 96.0 88.0 – 105.0 98.0 88.0 – 108.0 0.399
Hba1c (%) 5.5 5.1 – 5.9 5.7 5.2 – 6.1 0.031
insulin (mcU/ml) 12.2 8.0 – 17.2 12.0 7.9 – 17.0 0.971
alT 21.0 17.0 – 29.0 22.0 18.0 – 31.0 0.102
aST 22.0 18.0 – 32.0 22.0 18.0 – 31.0 0.835
Creatine phosphokinase 100.0 73.0 – 152.0 115.0 80.0 – 155.3 0.750
HOMa index 2.9 1.7 – 4.2 2.8 1.7 – 4.2 0.794
Notes: Mann–Whitney U test, median, interquartile range (iQR); achi-square test; fasting insulin/glucose (mg/dl) = ratio; glycemia (mg/dl) = fasting blood sugar.
Abbreviations: ap, armolipid plus®; HDl-C, high-density lipoprotein cholesterol; HOMa, homeostatic model assessment; lDl-C, low-density lipoprotein cholesterol; 
TG, triglycerides; lOpi, lopiGliK®.
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patients with LDL-C levels <130 mg/dL was 63% higher in 
the LOPI compared to the AP group. The evidence-based 
medicine (EBM) analysis showed that RR was 1.63 (95% CI; 
1.40–2.00), the RRR was 63.30% (95% CI; 36.60–95.20), 
the ARR was 26.20% (95% CI; 17.90–34.50), and the NNT 
was 4 (95% CI; 5.60–2.90; P<0.001).
Secondary outcomes
Survival analysis and HR of CVD linked to 38.67 mg/
dl reduction of lDl-C levels
The percentage of patients who achieved a 38.67 mg/dL 
reduction of LDL-C levels was 25.6% (52/203) in the AP 
group and 42.2% (156/370) in the LOPI group; this difference 
was statistically significant (P<0.001). The Kaplan–Meier 
survival curve (Figure 2) depicts the superiority of LOPI 
compared to AP and the application of the log-rank test 
(Mantel–Cox) demonstrated a statistically significant differ-
ence between the two products (P<0.002).
The HR was 0.761 (95% CI; 0.62–0.94), meaning that 
patients in the LOPI group reduced their risk of LDL-C 
being >38.67mg/dL by 23.9% compared to the AP group 
(P<0.011).
Hba1c levels assessed at baseline and 
after 16 weeks
Both treatments produced a statistically significant reduction 
at 16 weeks (P<0.001) as shown in Table 2, but a statisti-
cally significant difference between the two groups was not 
found at the end of the study (P=0.156). A 1% reduction of 
HbA1c was achieved in the AP group by 54.7% (111/203) 
of the patient population, in the LOPI group this value was 
achieved by 57.8% (214/370); this difference was not statisti-
cally significant (P=0.466).
Survival analysis and HR of CVD linked 
to 1% reduction of Hba1c levels
The Kaplan–Meier survival curve (Figure 3) has shown a 
difference between LOPI and AP groups, which was not 
statistically significant (P=0.411).
Cox proportional hazards regression analysis provided 
an HR of 91% or 0.91 (95% CI, 0.70–1.18), meaning that 
the patients in the LOPI group reduced by 9% their risk of 
having their HbA1c 1% higher compared to the other group; 
this result was not statistically significant (P=0.464).
Costs
The cost per unit of intervention was €2.11 (€122.64/58.1%) 
for LOPI, and €3.77 (€122.64/41.4%) for AP. The cost per 
cure was €211 for LOPI and €377 for AP; 58.1% and 32.5% 
Figure 2 Kaplan–Meier curve showing effect of lOpi and ap on 38.67 mg/dl 
lDl-C reduction.
Abbreviations: ap, armolipid plus®; lDl-C, high-density lipoprotein cholesterol; 
lOpi, lopiGliK®. 
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Table 2 Hba1c levels at baseline and at 16 weeks according to 
each nutraceutical
HbA1c % at 
baseline
HbA1c % after  
16 weeks
Nutraceuticals Median IQR Median IQR P-value
ap 5.5 5.1–5.9 5.4 5.0–5.8 <0.001
lOpi 5.7 5.2–6.1 5.5 5.0–6.0 <0.001
Notes: Wilcoxon sign rank test. Median/iQR.
Abbreviations: ap, armolipid plus®; iQR, interquartile range; lDl-C, high-density 
lipoprotein cholesterol; lOpi, lopiGliK®. 
Figure 3 Kaplan–Meier curve showing effect of lOpi and ap on 1% reduction of 
Hba1c.
Abbreviations: ap, armolipid plus®; lOpi, lopiGliK®. 
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were the differences between the percentages of people who 
had LDL-C <130 mg/dL at baseline and at the end of the 
study for each product.
Safety
Ten side effects were recorded: three in the LOPI group 
(0.8%) and seven in the AP group (3.4%) (P=0.041). The 
subjects in the LOPI group reported myalgia (two cases) 
and constipation (one case), while those in the AP group 
complained of myalgia (two cases), diarrhea (two cases), 
nausea (two cases), and itch (one case).
Discussion
Reduction of lDl-C and Hba1c
The results of this single blind, multicenter, randomized 
controlled trial confirm the efficacy of NUTs in lowering 
plasma lipid levels. AP and LOPI had an important effect on 
the primary outcome: reduction of LDL-C levels <130 mg/
dL. At baseline there was no statistical difference between 
the percentages of patients in the two groups with LDL-C 
<130 mg/dL. At the end of the study, a strong statistical 
difference was found between the two groups of patients 
(P<0.001). The percentage of patients who achieved 
LDL-C levels <130 mg/dL was 26% higher in the LOPI 
group. The effectiveness analysis showed evidence of the 
superiority of LOPI compared to AP. LOPI patients were 
three times more likely to achieve LDL-C levels <130 mg/
dL; NNT was 4.
It has been suggested that the superior effectiveness of 
LOPI could be linked to the presence of Morus alba, which 
may contribute to the enhanced cholesterol-lowering action.12 
At the end of the study, there was a statistically significant 
reduction in the HbA1c levels in both groups. LOPI showed 
a greater difference between the median HbA1c levels at 
baseline and at the end of the study (5.7%–5.5%=0.2%) 
compared to AP (5.5%–5.4%=0.1%). Both products achieved 
a 1% HbA1c reduction, but the difference between groups 
(AP vs LOPI) was not statistically significant.
Clinical and economic implication of 
38.67 mg/dl lDl-C reduction and 1% 
Hba1c reduction on CVD risk
The survival analysis and the HR linked to 38.67 mg/dL 
LDL-C reduction demonstrated the superiority of LOPI 
vs AP. A statistically significant difference was found with 
LOPI reducing the risk of increased LDL-C >38.67 mg/dL 
by 24% compared to AP.
The results of very large, systematic literature review 
and meta-analysis including 312,175 patients from 49 trials 
suggested that the RR for major vascular event per 38.67 
mg/dL reduction of LDL-C was 0.77 (95% CI; 0.71–0.84; 
P<0.001).16 In our study, the reduction of 38.67 mg/dL pro-
vided an HR (instantaneous risk reduction) of 0.76 (95% CI; 
0.62–0.94; P<0.011) in the LOPI group. A series of studies 
conducted between 1980 and 2010, one in the US27 and in 
Canada,28 eight in Europe,29–36 estimated that 19%–46% of 
the total reduction in the rate of CHD mortality was explained 
by the reduction in total cholesterol levels. As previously 
mentioned, it has been demonstrated that for each 38.67 mg/
dL reduction of LDL-C achieved, the risk of CVD is reduced 
by 20%.8 The EUROASPIRE III health economic project 
demonstrated that prevention is cost-effective.37 Therefore, 
reducing the risk means reducing the costs. Some observa-
tional studies have suggested that higher HbA1c levels were 
associated with CVD and death.38–40 It has been demonstrated 
that every 1% increment of HbA1c was positively associated 
with the risk of total CVD (HR: 1.2, 95% CI; 1.08–1.34) and 
the risk of death (HR: 1.12, 95% CI; 1.03–1.26).41 In our 
study, LOPI reduced the HR by 9% (HR =0.91) compared to 
AP, but this reduction was not statistically significant.
Costs
While the two products had the same retail price, the cost 
per unit of intervention and per cure of LOPI was 44% lower 
than AP; for this reason, we can assume that LOPI provides 
better value for money. Cost of treatments are a hot topic 
today, because public/private payers and providers are always 
looking for the best medication or treatment in clinical and 
economic terms.
Safety
Both products have shown similar safety profiles.
Strengths and limitations
This study aimed to assess the difference between two NUT 
products, it was appropriately powered, and conducted in four 
Italian regions. The patient was the unit of randomization and 
the unit of intervention, but the randomization was 2:1 and 
not 1:1 which is considered the best randomization ratio. In 
fact, some differences may arise between equal or unequal 
randomization. Equal randomization (1:1) is statistically the 
most efficient method because, for any given total sample 
size the most power to detect a difference is achieved with 
equal group size. Unequal randomization (2:1 as in our case) 
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can be justified by practical reasons such as to minimize the 
exposure to a new treatment or for cost implications because 
1:1 is usually a more expensive option. Nevertheless, the 
power achieved in our study was very high. The length of 
treatment during the study (16 weeks) could also be a source 
of bias because many studies are conducted for longer 
periods of time. A short study providing a short follow-up, 
could increase or decrease possible changes in the primary 
and secondary outcomes. It was not possible to conduct a 
health economic evaluation because direct medical costs, 
direct non-medical costs, and all the costs incurred by the 
patients were not gathered during the study. Furthermore, 
it was deemed too expensive and time consuming to build 
an economic model using secondary data. NUTs is a new 
growing area of interest in Italy and in the rest of Europe, 
and to the best of our knowledge, there have been no health 
economic studies conducted in Italy in this regard, which 
could have informed our model.
The results of this study support the conclusion of other 
studies that suggest NUTs can be used as alternatives to 
lipid-lowering medications.9,11
Our results are in line with the SISA guidelines, which 
suggest that the cholesterol-lowering effect of some NUTs 
is consistent, and it is supported by scientific evidence.10
This study provides evidence of the clinical superiority 
of LOPI compared to AP in lowering LDL-C and CVD risk, 
showing better value for money as well.
Conclusion
The European Cardiovascular Disease Statistics 20172 and 
the economic costs of CVD from 2014 to 2020 in six Euro-
pean economies3 have suggested that the cost of CVDs are 
going to increase in Europe. Therefore, a NUT that lowers 
the CVD risk  and is potentially value for money, could be 
an asset for patients, practitioners, health care system and 
the society as well.
This study has also uncovered a new need: health eco-
nomic evaluation in the area of NUTs.
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